| Old Articles: <Older 1081-1090 Newer> |
|---|
 |
IDB America
March 2004
Roger Hamilton |
From our forest to your medicine cabinet How a unique scientific institution helps Costa Rican firms to profit from bioprospecting   |
The Motley Fool
March 26, 2004
Charly Travers |
Human Genome Getting on Track What a novel concept for a drug company to focus on commercializing drugs. |
BusinessWeek
April 5, 2004
Gene G. Marcial |
How Caraco Could Get Swallowed Some pros think India's Sun Pharmaceutical is out to acquire Caraco. |
The Motley Fool
March 24, 2004
Bill Mann |
Reddy or Not Dr. Reddy's is an Indian company with a booming business in pharmaceutical ingredient development and branded medications that it sells throughout the developing world. |
The Motley Fool
March 23, 2004
David Nierengarten |
Genentech's Star Power How much higher can Genentech go? |
BusinessWeek
March 29, 2004
Kerry Capell |
A Drug Behemoth In The Making? Novartis plus Aventis would create the world's No. 2 drugmaker, unless politics get in the way |
The Motley Fool
March 22, 2004
Seth Jayson |
Stent Wars Going Strong New studies show stents do little to stop heart attacks. What does that mean for stent makers? |
Fast Company
April 2004
Keith H. Hammonds |
Moment of Truth? It has been a tortuous year for Harry M. Jansen Kraemer Jr., CEO of Baxter International Inc. Back in November 2002, we lauded Kraemer's forthright leadership as his company confronted the deaths of 53 patients due to contaminated dialysis filters made by a Baxter subsidiary. Now Kraemer is out of a job. |
The Motley Fool
March 19, 2004
Bill Mann |
The Drug Reimportation Disaster State-imposed pricing is not natural law. Expect Canada to have a problem supplying all those drugs. |
Bio-IT World
March 17, 2004 |
High-Performance Computing Life science companies are solving big problems with home-grown clusters, racks of blades, and gangs of PCs working overtime. |
| <Older 1081-1090 Newer> Return to current articles. |
